Durvalumab Approved by FDA for Reducing NSCLC Progression
February 19th 2018The FDA recently approved durvalumab (Imfinzi) for the treatment of patients with stage 3 non-small cell lung cancer (NSCLC) whose tumors are unresectable and whose disease has not progressed following treatment with chemoradiation.
Read More